Pretty Bad Rating Given to Amphastar Pharmaceuticals (NASDAQ:AMPH) By a Raymond James

February 15, 2018 - By Winifred Garcia

 Pretty Bad Rating Given to Amphastar Pharmaceuticals (NASDAQ:AMPH) By a Raymond James

Investors sentiment increased to 0.91 in Q3 2017. Its up 0.15, from 0.76 in 2017Q2. It improved, as 11 investors sold Amphastar Pharmaceuticals, Inc. shares while 32 reduced holdings. 10 funds opened positions while 29 raised stakes. 20.04 million shares or 0.68% less from 20.18 million shares in 2017Q2 were reported.

Sei Invests has invested 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Geode Capital Management Llc has 327,389 shares. State Of Tennessee Treasury Department reported 31,786 shares. 12,700 are held by Teachers Retirement Systems Of The State Of Kentucky. Texas Permanent School Fund stated it has 0.01% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Bluestein R H And Company has invested 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Jpmorgan Chase reported 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Gsa Llp reported 0.03% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Comerica State Bank holds 37,490 shares. Alaska-based State Of Alaska Department Of Revenue has invested 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Barclays Public Ltd has invested 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). 280,328 are owned by Principal Fincl Group. Ubs Asset Americas reported 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Loomis Sayles & Ltd Partnership, a Massachusetts-based fund reported 1,799 shares. Blackrock reported 5.51 million shares.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Receives a Downgrade

Raymond James lowered Amphastar Pharmaceuticals (NASDAQ:AMPH) shares, lowering their rating to a “Hold” in an analyst note issued to clients on 9 November. Trading on the $870.32M market cap AMPH will be interesting to observe today.

Investors sentiment increased to 0.91 in Q3 2017. Its up 0.15, from 0.76 in 2017Q2. It improved, as 11 investors sold Amphastar Pharmaceuticals, Inc. shares while 32 reduced holdings. 10 funds opened positions while 29 raised stakes. 20.04 million shares or 0.68% less from 20.18 million shares in 2017Q2 were reported.

Sei Invests has invested 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Geode Capital Management Llc has 327,389 shares. State Of Tennessee Treasury Department reported 31,786 shares. 12,700 are held by Teachers Retirement Systems Of The State Of Kentucky. Texas Permanent School Fund stated it has 0.01% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Bluestein R H And Company has invested 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Jpmorgan Chase reported 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Gsa Llp reported 0.03% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Comerica State Bank holds 37,490 shares. Alaska-based State Of Alaska Department Of Revenue has invested 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Barclays Public Ltd has invested 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). 280,328 are owned by Principal Fincl Group. Ubs Asset Americas reported 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Loomis Sayles & Ltd Partnership, a Massachusetts-based fund reported 1,799 shares. Blackrock reported 5.51 million shares.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Ratings Coverage

Among 6 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Amphastar Pharmaceuticals has $26.0 highest and $16.0 lowest target. $20.67’s average target is 9.19% above currents $18.93 stock price. Amphastar Pharmaceuticals had 26 analyst reports since August 10, 2015 according to SRatingsIntel. On Thursday, November 9 the stock rating was downgraded by Raymond James to “Hold”. Jefferies maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on Thursday, November 9 with “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Friday, July 28. Wells Fargo initiated the stock with “Outperform” rating in Friday, February 19 report. Needham maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on Friday, September 15 with “Buy” rating. Jefferies maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) rating on Friday, June 9. Jefferies has “Buy” rating and $2000 target. The stock of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has “Buy” rating given on Tuesday, September 26 by Needham. BMO Capital Markets maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on Thursday, October 26 with “Hold” rating. BMO Capital Markets maintained the shares of AMPH in report on Friday, November 10 with “Market Perform” rating. The firm has “Hold” rating by Zacks given on Tuesday, August 18.

The stock increased 0.91% or $0.17 during the last trading session, reaching $18.93. About 76,725 shares traded. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has risen 8.19% since February 15, 2017 and is uptrending. It has underperformed by 8.51% the S&P500.

Analysts await Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report earnings on March, 12. They expect $-0.04 EPS, up 33.33 % or $0.02 from last year’s $-0.06 per share. After $0.07 actual EPS reported by Amphastar Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -157.14 % negative EPS growth.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $870.32 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

More notable recent Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news were published by: Globenewswire.com which released: “Amphastar Announces Approval for Medroxyprogesterone Acetate Injectable …” on November 29, 2017, also Seekingalpha.com with their article: “Amphastar Pharmaceuticals’ (AMPH) Management on Q2 2017 Results – Earnings …” published on August 10, 2017, Reuters.com published: “Momenta seeks $938 million from Amphastar at drug patent trial’s end” on July 20, 2017. More interesting news about Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) were released by: Seekingalpha.com and their article: “Amphastar Pharmaceuticals’ (AMPH) Management on Q3 2017 Results – Earnings …” published on November 08, 2017 as well as Globenewswire.com‘s news article titled: “Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended …” with publication date: May 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.